The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ALS and acquired Mexico City-based ARJ
  • ARJ is the largest, private pharmaceutical testing lab in Latin America
  • Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America
  • ALS states the acquisition of ARJ supports its strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America

Brisbane-based ALS has acquired Laboratorios de Control ARJ (ARJ).

ALS is a leading testing, inspection, certification and verification company trying to expand its global presence.

Based in Mexico City, ARJ is the largest, private pharmaceutical testing lab in Latin America with revenues of over $30 million.

ARJ was founded in 1967 and has steadily grown its business, employing over 500 people. It specialises in providing quality control for medicines, biological products, generics, biosimilars, cosmetics and medical devices. It also services many of the world’s largest pharmaceutical companies.

Mexico is a growing contributor to the $20 billion global pharmaceutical testing market and an important hub for Latin and North America.

“ARJ has a world class operation and client base which offers us a strong platform to continue to grow our presence in key markets including Argentina, Brazil, Colombia, and Mexico. We welcome the ARJ team to ALS and look forward to our collaboration with them throughout the region,” ALS Managing Director and CEO Raj Naran said.

ALS’ acquisition of ARJ is supported by the company’s existing Life Sciences Latin America operations and is expected to benefit from Group’s regional and global presence to further expand their offerings to clients.

“The acquisition of ARJ aligns with our stated acquisition strategy focusing on food and pharmaceutical opportunities in key growth markets such as Latin America,” Raj said.

ALQ by the numbers
More From The Market Online
The Market Online Video

Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie

From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
Lung imaging concept

Biotech lung imaging darling 4DX Medical back at $2.20/sh on Miami U contract

4DX Medical has seen its price jump back to $2.20/sh, as its next-gen lung imaging scan…
Chuffed bloke

Race Oncology’s placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums…

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…